CD22 and Burkitt lymphoma: The diagnosis of BL and DLBCL is more complex when implemented than in principle; despite that, various methods may assist in establishing the diagnosis, including histomorphology, immunophenotyping, and genetic testing [1,69]. Immunophenotyping assays frequently used in diagnosing BL and DLBCL include pan-B-cell markers (CD19, CD20, CD22, CD79a, and PAX5), BCL-2, BCL-6, MUM-1, CD10, ki-67, and c-MYC [6,22,69].